Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/13/2005US20050227978 Fibrosis inhibitor
10/13/2005US20050227977 Substituted 1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione compounds and methods for the treatment of pain
10/13/2005US20050227976 Novel hydroxamates as therapeutic agents
10/13/2005US20050227975 Treatment of inflammatory and obstructive respiratory complaints; 1-{3-[2-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-ethylamino]-3-methyl-butyl}-6-methoxy-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; potent, high degree of selectivity to the beta 2-adreno-receptor
10/13/2005US20050227974 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
10/13/2005US20050227973 Human adam-10 inhibitors
10/13/2005US20050227972 treating disorders of the cardiovascular system; adenosine receptor agonists/antagonists
10/13/2005US20050227971 Thioamide derivatives as progesterone receptor modulators
10/13/2005US20050227970 3-Benzyl-2-(4-trifluoromethyl-3-pyridylcarbonyl)imino-4-thiazolidone; durability; low concentrations; good spectrum of action; insecticides; miticides; nematocides; helminths
10/13/2005US20050227969 A piperidin-2-one, 1,3-oxazinan-2-one, or 1,3-thiazinan-2-one compound for treatment of glaucoma, mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts; 7-{(4S)-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; side effect reduction
10/13/2005US20050227967 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
10/13/2005US20050227966 Bazedoxifene acetate formulations
10/13/2005US20050227965 Crystalline polymorph of bazedoxifene acetate
10/13/2005US20050227964 Bazedoxifene ascorbate
10/13/2005US20050227963 Antiinflammatory agents
10/13/2005US20050227961 Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
10/13/2005US20050227960 N-[(octahydrocyclopenta[c] pyrrol-5-ylcarbamoyl)methyl]-3 -trifluoromethylbenzamide trifluoroacetic acid salt; monocyte chemotactic proteins (MCP-1) receptor antagonist or partial agonists; antiinflammatory agent, antiallergen, autoimmune diseases; rheumatoid arthritis, atherosclerosis, asthma
10/13/2005US20050227959 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; excellent inhibitory activity on STAT6 activation and effective against allergic diseases
10/13/2005US20050227958 Polycyclic pyridines as potassium ion channel modulators
10/13/2005US20050227957 Therapy for oxidation stresses; complex of drug and enzyme mimetics; lipophilic cation moiety covalently bonded to glutathione peroxidase mimetic moiety is selected from the group consisting of: benzisoselenazolones, diaryl diselenides and diaryl selenides
10/13/2005US20050227954 Hypoglycemic agent
10/13/2005US20050227953 Azacyclosteroid histamine-3 receptor ligands
10/13/2005US20050227952 Extended cycle multiphasic oral contraceptive method
10/13/2005US20050227951 Verification of translation
10/13/2005US20050227949 Compositions and methods for treatment of viral and bacterial infections
10/13/2005US20050227948 Hif hydroxylase inhibitors
10/13/2005US20050227947 Phosphonate analogs for treating metabolic diseases
10/13/2005US20050227946 administering to a mammal in need thereof an effective amount of a cyclic compound substituted by at least three vicinal phosphorus containing radicals; medicament providing a growth factor modulating activity in mammals
10/13/2005US20050227944 and adjuvants to reduce cholesterol levels of the plasma membrane of the infected host cells; disrupting efficient attachment and internalization of the parasite to macrophage cells; antiprotozoa agents
10/13/2005US20050227942 Use of Asialo-Gm1 (Agm1,) and/or GM gangliosides, and substances which simulate carbohydrate moiety of these gangliosides with regard to binding to anti-AGM1 antibodies and/or anti-GM1 antibodies, for the preparation of an agent for binding or blocking anti-AGM1 antibodies and/or anti-GM1 antibodies
10/13/2005US20050227941 Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
10/13/2005US20050227937 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
10/13/2005US20050227932 Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
10/13/2005US20050227930 Cholesterol lowering combination
10/13/2005US20050227929 parecoxib sodium and antineoplastic agent chosen from list of 150 compounds, vaccines, and biodrugs such as polyglutamic acid-paclitaxel
10/13/2005US20050227928 Glycoalkaloid compositions and various uses thereof
10/13/2005US20050227927 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
10/13/2005US20050227919 DNA damage repair inhibitors for the treatment of cancer
10/13/2005US20050227915 Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
10/13/2005US20050227911 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
10/13/2005US20050227910 Local regional chemotherapy and radiotherapy using in situ hydrogel
10/13/2005US20050227327 Nicotinamide riboside kinase compositions and methods for using the same
10/13/2005US20050227285 Control of gene expression in eukaryotic cells
10/13/2005US20050227249 Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
10/13/2005US20050227233 Method for diagnosing and treating schizophrenia
10/13/2005US20050226990 Fortified confectionery products
10/13/2005US20050226948 Methods for enhancing the transport of glucose into muscle
10/13/2005US20050226945 Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
10/13/2005US20050226943 Extract of sophora flavescens flavonoids and uses thereof
10/13/2005US20050226941 Composition for controlling excessive calorie intake-induced disorder, food product for controlling excessive calorie intake-induced disorder, skin preparation for external use for controlling
10/13/2005US20050226940 Antitumour compositions containing taxane derivatives
10/13/2005US20050226934 Inclusion complexes of active compounds in acrylate (co)polymers and methods for their production
10/13/2005US20050226932 Pharmaceutical formulations for itraconazole
10/13/2005US20050226930 A bi-layer tablet with the first layer containing dextromethorphan hydrobromide and oxycodone hydrochloride, and the second layer containing carboxy methyl cellulose, sodium chloride, and iron oxide, and does not contain an opoid antagonist; side effect reduction
10/13/2005US20050226928 Synergistic mixture; hypoglycemic agents; sustained release; bioavailability; metformin with thiazolidinedione compound
10/13/2005US20050226927 Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
10/13/2005US20050226926 Sustained-release tablet composition of pramipexole
10/13/2005US20050226925 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
10/13/2005US20050226924 Composition comprising itraconazole for oral administration
10/13/2005US20050226923 Venlafaxine compositions in the form of microtablets
10/13/2005US20050226922 Apparatus and method for transdermal delivery of fentanyl-based agents
10/13/2005US20050226920 Method of decreasing nicotine withdrawal symptoms during smoking cessation.
10/13/2005US20050226919 Device for transdermal administration for the treatment of urinary tract disorders
10/13/2005US20050226916 Hemostatic polymer useful for RAPID blood coagulation and hemostasis
10/13/2005US20050226910 Transdermal drug delivery system
10/13/2005US20050226908 Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
10/13/2005US20050226907 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
10/13/2005US20050226906 Nutrient system for individualized responsive dosing regimens
10/13/2005US20050226903 Water-dispersible or water-soluble poloxamers provides a drug forms with good fracture strength, flexibility, and dimensional stability; counteract triglycerides brittleness; use of a medical stick for medical administration in body cavities and/or wound cavities; veterinary medicine
10/13/2005US20050226898 Compositions and methods for transdermal oxybutynin therapy
10/13/2005US20050226884 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy
10/13/2005US20050226879 Methods and compositions related to inhibiting nuclear envelope breakdown
10/13/2005US20050226878 Immune Response Modifiers; toll-like receptor 7, 8, or 9 agonists; imidazonaphthyridine, oxazolo- or thiazolo-naphthyridine, quinoline, or pyridine amines, and an antiinflammatory glucocorticoid, immunosuppressant, or immunotherapeutic, or a non-steroidal antiinflammatory agent; side effect reduction
10/13/2005US20050226871 Using mixture of fk-506 and geldanamycin compound immobilized onto polypeptide; both compounds bind to polypeptide components of steroid receptor complexes, hsp90 and FKBP52, respectively
10/13/2005US20050226870 Administering anti-inflammatory amount of a purified antibody specific against C5, wherein antibody inhibits the cleavage of C5 into C5a and C5b
10/13/2005US20050226862 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders and for identifying agents therapeutic therefor
10/13/2005US20050226858 Compositions containing reduced coenzyme Q10 and carotenoid
10/13/2005US20050226844 Valency platform molecules comprising carbamate linkages
10/13/2005US20050226840 Use of creatine or creatine compounds for skin preservation
10/13/2005US20050226823 Film-shaped preparations with improved chemical stability containing active substances and method for the production thereof
10/13/2005US20050226818 Anticholinergic powder formulations for inhalation
10/13/2005US20050226814 Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid
10/13/2005US20050224746 improving the hand or feel of the fabric; good oil repellency
10/13/2005US20050224524 Aerosol
10/13/2005US20050224372 Multiple compartment bag assembly for dialysis fluid
10/13/2005US20050224084 Sensory integration therapy aid and method
10/13/2005DE19829844B4 Verwendung von D-Galaktose zur Verhinderung von Nekrosen Use of D-galactose to prevent necrosis
10/13/2005DE10393799T5 Kinaseinhibitoren für die Behandlung von Erkrankungen Kinase inhibitors for the treatment of diseases
10/13/2005DE10393729T5 Verfahren zur Behandlung von Emesis A method of treating emesis
10/13/2005DE10392134T5 Azaphenylalaninderivate Azaphenylalaninderivate
10/13/2005DE102005026278A1 Composition for use as a cosmetic or pharmaceutical, e.g. as a depilatory or peeling composition, comprises alkene homo- or co-polymer wax prepared by metallocene catalysis
10/13/2005DE102004020890A1 Salbe zur Behandlung von oder Prophylaxe vor Nagelbettentzündung Ointment for the treatment or prophylaxis of nail bed inflammation
10/13/2005DE102004014841A1 Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms Use of rotigotine for the treatment and prevention of Parkinson's plus syndrome
10/13/2005DE102004014616A1 Microbially stable cosmetic or dermatological light-protective skin care preparations, containing taurine and paraben, sorbic acid or (3-iodo-2-propynyl) N-butylcarbamate
10/13/2005DE102004012921A1 New 7-butynyl-8-(3-amino-1-piperidinyl)xanthine derivatives useful as dipeptidyl peptidase IV inhibitors, e.g. for treating diabetes, arthritis, obesity and osteoporosis
10/13/2005CA2794424A1 Multi-vitamin and mineral nutritional supplements
10/13/2005CA2602596A1 Compositions and methods for improved mucus function
10/13/2005CA2582428A1 Modified pectins, compositions and methods related thereto
10/13/2005CA2575740A1 Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods
10/13/2005CA2564643A1 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
1 ... 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 ... 7860